|Summary sheet: MET|
|Common names||MET, Methylethyltryptamine|
|Routes of Administration|
N-Ethyl-N-methyltryptamine (also known as Methylethyltryptamine, and MET) is a lesser-known novel psychedelic substance of the tryptamine class that produces powerful and short-lived psychedelic effects when administered. It is structurally related to DMT and is similarly unique among psychedelics due to its short-lived effects, rapid onset and progressive stages.
The fumarate salt has been reported as being active via smoking/vaporization at 15-65 mg and orally at 80-110 mg. When smoked or vaporized it has been reported to produce effects similar to those of DMT with some distinct stylistic variations which include a more grounded headspace, stimulating physical effects, and reduced subjective intensity.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MET, and it has a very brief history of human usage. Today, it is either used recreationally or as an entheogenic substance and has been exclusively distributed by online research chemical vendors since mid-2016. Due to its unstudied properties and effects, it is highly advised to approach this novel psychedelic substance with the proper precautions and harm reduction practices if choosing to use it.
MET, or N-ethyl-N-methyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure that comprises a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. Unlike DMT, which contains two methyl groups, MET contains groups of one methyl and one ethyl carbon chains bound to the terminal amine RN of its tryptamine backbone.
As with most psychedelic tryptamines, MET is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from MET's binding efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continue to remain elusive.
There is very little information on the human pharmacology or toxicity of MET. The freebase is believed to be active via vaporization at 15 mg and orally at 80-100 mg.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
This compound has very similar effects to that of DMT when smoked or vaporized. Its visual effects, such as geometry and internal hallucinations, are almost identical with the exception of being slightly brighter and synthetic in their overall appearance. The head space, however, has been reported to be considerably more stimulating, grounded, and less jarring than the head space of DMT, which has led some to describe it as a more recreational variant of DMT. In contrast to DMT, it also produces a noticeably pleasurable body high that is similar to that of 5-MeO-DMT although not as intensely nauseating or overwhelming.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Spontaneous physical sensations
- Physical euphoria - This compound has been reported to be intensely euphoric in a manner which results from its powerful tactile enhancement alongside the production of pleasurable sensations across the body. It has been compared to the physically euphoric effects of 5-MeO-DMT although less encompassing or overwhelming.
- Tactile enhancement
- Bodily control enhancement
- Increased heart rate
- Increased blood pressure
- Temperature regulation suppression
- Muscle relaxation
- Muscle cramps
- Teeth grinding
- Excessive yawning
- Pupil dilation
- Colour enhancement
- Colour replacement
- Colour shifting
- Pattern recognition enhancement
- Visual acuity enhancement
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Environmental patterning
- Perspective distortions
- Scenery slicing
- Symmetrical texture repetition
- After images
- Brightness alteration
The visual geometry produced by this compound can be described as somewhat similar in appearance to that of DMT, 4-HO-MET and DET. It can be comprehensively described through its variations as intricate in complexity, abstract in form, equally synthetic and organic in style, structured in organization, extremely brightly lit and multicoloured in scheme, glossy in shading, equally sharp and soft in its edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in depth and consistent in intensity. The visuals have a contradictory natural and synthetic feel to them which is reminiscent of both LSD and psilocybin.
- Conceptual thinking
- Cognitive euphoria
- Creativity enhancement
- Emotion enhancement
- Empathy, affection, and sociability enhancement
- Focus suppression
- Immersion enhancement
- Novelty enhancement
- Increased music appreciation
- Laughter fits
- Increased libido
- Memory suppression
- Language suppression
- Personal bias suppression
- Thought loops
- Thought connectivity
- Time distortion
- Déjà vu
- It should be noted that these effects are the rarest and least reproducible those that can occur during a psychedelic experience. They are considered unique in that that simply taking more of the substance does not necessarily increase the chance they will occur, and are said to rely more on contextual factors such as the user's set and setting rather than the substance or dose itself. Their fullest manifestations are sometimes called "peak", "transcendent" or "transformative" experiences; however, they can still occur on a conceptual or cognitive level that can leave a lasting positive impact on the user.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MET use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MET is a research chemical with very little history of human usage. Anecdotal evidence from people within the community who have tried MET suggest that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
Early reports suggest MET is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics it is most widely thought to be self-regulating.
As with DMT, tolerance to the effects of MET does not readily occur, though its extended residual effects indicate a mild form of tolerance may be present when used in quick succession. However, it presents little to no cross-tolerance with other psychedelics, meaning that after the consumption of MET psychedelics will not display a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Due to its relative obscurity, the possession and sale of MET is unscheduled in most countries.
- Germany: MET is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Japan: MET is a controlled substance in Japan as of March 20, 2023.
- New Zealand: MET is an analogue of DMT, so is a Class C controlled substance in New Zealand.
- Switzerland: MET is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- United Kingdom: MET is a Class A controlled substance in the UK under a generic clause originally added in 1977 that covers derivatives of tryptamine that are modified by alkyl substitution at the nitrogen atom of the tryptamine side chain.
- United States: MET is unscheduled in the United States. However, it is likely that it would be considered a controlled substance analogue of DMT or DET, in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act.
This article does not cite enough references.
You can help by adding some.
- “That’s okay, you’re good” MET trip report, The Vaults of Erowid
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- 危険ドラッグの成分７物質を新たに指定薬物に指定 (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved March 11, 2023.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "The Misuse of Drugs Act 1971 (Modification) Order 1977". The National Archives. July 26, 1977. Retrieved January 10, 2020.